Bioequivalence Evaluation of Two Brands of Lisinopril Tablets by in vitro Comparative Dissolution Test and in vivo Bioequivalence Test

Abstract

The bioequivalence of a test formulation (Nanopril®, “test”) and a reference formulation (“reference”) of lisinopril (CAS 83915-83-7) was demonstrated by in vivo and in vitro tests. The in vivo bioequivalence study in 26 healthy volunteers was designed as a single dose, randomized, double-blind trial with a 2-week washout period between the doses. Prior to the in vivo study, an in vitro comparative dissolution test was performed by the paddle method following the bioequivalence guidance of the Korea Food and Drug Administration (KFDA). By the results of the dissolution test it was demonstrated from the similar and rapidly dissolving patterns of the two lisinopril tablets that the two formulations were pharmaceutically equivalent. However, the in vivo bioequivalence study was required to fully evaluate the bioequivalence of the two drug products. In the in vivo bioequivalence study, the plasma samples drawn from the volunteers were analyzed utilizing a sensitive LC-MS-MS analysis method and the bioequivalence between the two drug products was assessed by statistical analysis of the log transformed mean ratios of C_max, AUC_0–tand AUC_0–∞. The mean maximum concentration (C_max) of the test and reference were found to be 60.41 ± 20.07 ng/mL^–1 and 61.11 ± 19.36 ng/mL, respectively. The 90% confidence intervals (C.I.) of C_max were in the range from 0.91 to 1.08. As for the AUC_0–t and the AUC_0–∞, test values were 792.73 ± 273.41 ng · mL^–1 · h, 862.74 ± 303.81 ng · mL^–1 · h and the reference values were 841.66 ± 286.07 ng · mL^–1 · h, 906.97 ± 318.72 ng · mL^–1 · h, respectively. The 90% C. I. of AUC_0–twere 0.86 to 1.01 and of AUC_0–∞0.87 to 1.02 and thus were within the 80–125% interval proposed by the FDA. In addition to the 90% C. I. of the pharmaceutical parameters, a two-way ANOVA showed no significant difference between the two formulations. Based upon these statistical analyses, it was concluded that the test formulation is bioequivalent to the reference.

Key words

Angiotensin converting enzyme inhibitors - CAS 83915-83-7 - Lisinopril, bioequivalence, dissolution - Nanopril®

• References

• 1 El-Emam AA, Hansen SH, Moustafa MA, El-Ashry SM, El-Sherbiny DT. Determination of lisinopril in dosage forms and spiked human plasma through derivatization with 7-chloro-4-nitrobenzo-2-oxa-1,3-diazole(NBD-Cl) followed by spectrophotometry or HPLC with fluorimetric detection. J Pharm Biomed Anal. 2004; 34: 35-44
• 2 Sagirli O, Ersoy L. An HPLC method for the determination of lisinopril in human plasma and urine with fluorescence detection. J Chromatogr B. 2004; 809: 159-165
• 3 Padua AAF, Barrientos-Astigarraga RE, Rezende VM, Mendes GD, Nucci GD. Lisinopril quantification in human plasma by liquid chromatography-electrospray tandem mass spectrometry. J Chromatogr B. 2004; 809: 211-216
• 4 Brown NJ, Vaughan DE. Angiotensin-Converting Enzyme Inhibitors. Circulation. 1998; 97: 1411-1420
• 5 Jocobi I, Schmieder RE. Nephroprotection by antihypertensive therapy. Basic Res Cardiol. 1998; 93 (Suppl 2) 109-119
• 6 Chrysant SG, Chrysant GS. Pharmacological and clinical profile of moexipril: A concise review. J Clin Pharmacol. 2004; 44: 827-836
• 7 Rosenthal T, Ben-arie I, Carrol I, Fiedel I, Kisch E, Leiba M et al. Improving quality of life in patients with hypertension: lisinopril as a replacement therapy. Curr Ther Res Clin Exp. 1995; 56: 57-61
• 8 Tamimi III, Salem II, Alam SM, Zaman Q, Dham R. Bioequivalence Evaluation of Two Brands of Lisinopril Tablets (Lisotec and Zestril) in Healthy Human Volunteers. Biopharm Drug Dispos. 2005; 26: 335-339
• 9 Georgarakis M, Tsakalof A, Zougrou F, Kontopoulos G, Tsiptsios I. Evaluation of the bioequivalence and pharmacokinetics of two lisinopril tablet formulations after single oral administration in healthy volunteers. Arzneimittel-Forschung (Drug Research). 2004; 54 (1) 15-19
• 10 Huang I, Xu Y, Liu F, Gao S, Guo Q. Development of a liquid chromatography/tandem mass spectrometry assay for the quantification of lisinopril in human plasma. Rapid Commun Mass Spectrom. 2006; 20: 248-252
• 11 World Health Organization, Multisource (Generic) Pharmaceutical Products: Guidelines on Registration Requirements to Establish Interchangeability. 2005.
• 12 The United States Pharmacopeia The National Formulary, 29th ed. Rockville: United States Pharmacopeia Convention, Inc. 2006.
• 13 Aktas ES, Ersoy L, Sagirli O. A new spectrofluorimetric method for the determination of lisinopril in tablets. Il Farmaco. 2003; 58: 165-168
• 14 Razak OA, Belal SF, Bedair MM, Barakat NS, Haggag RS. Spectrophotometric and Polarographic determination of enalapril and lisinopril using 2,4-dinitrofluorobenzene. J Pharm Biomed Anal. 2003; 31: 701-711
• 15 El-Gindy A, Ashour A, Abdel-Fattah L, Shabana MM. Spectrophotometric, septrofluorimetric and LC determination of lisinopril. J Pharm Biomed Anal. 2001; 25: 913-922
• 16 Tsakalof A, Bairachtari K, Georgarakis M. Development of a liquid chromatography-mass spectrometry method for monitoring the angiotensin-converting enzyme inhibitor lisinopril in serum. J Chromatogr B. 2003; 783: 425-432
• 17 Leis HJ, Fauler G, Raspotnig G, Windischofer W. An improved method for the measurement of the angiotensin-converting enzyme inhibitor lisinopril in human plasma by stable isotope dilution gas chromatography/negative ion chemical ionization mass spectrometry. Rapid Commun Mass Spectrom. 1999; 13 (8) 650-653
• 18 Leis HI, Fauler G, Raspotnig G, Windischofer W. Quantitative Determination of the Angiotensin-converting Enzyme Inhibitor Lisinopril in Human Plasma by Stable Isotope Dilution Gas Chromatography/Negative Ion Chemical Ionization Mass Spectrometry. Rapid Commun Mass Spectrom. 1998; 12: 1591-1594
• 19 Korea Food and Drug Administration, KFDA Guideline for Bioequivalence Test. 2002.
• 20 Lipka E, Amidon GL. Setting bioequivalence requirements for drug development based on preclinical data: optimizing oral drug delivery systems. J Control Release. 1999; 62: 41-49